Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/jc.2009-2622PMID 20371660PMCID PMC2902076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction.

  2009cited by this paper
• The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis.

  2009cited by this paper
• Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid.

  2009cited by this paper
• Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

  2008cited by this paper
• Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

  2008cited by this paper
• EFFECTS OF FENOFIBRATE AND XUEZHIKANG ON HIGH‐FAT DIET‐INDUCED NON‐ALCOHOLIC FATTY LIVER DISEASE

  2007cited by this paper
• Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.

  2007cited by this paper
• Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.

  2007cited by this paper
• Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

  2006cited by this paper
• Impaired β-Cell Function in Human Aging: Response to Nicotinic Acid-Induced Insulin Resistance

  2006cited by this paper
• Fenofibrate, a peroxisome proliferator‐activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver

  2006cited by this paper
• Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance.

  2006cited by this paper
• Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

  2005cited by this paper
• Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.

  2005cited by this paper
• Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

  2005cited by this paper
• Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.

  2005cited by this paper
• Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk

  2004cited by this paper
• Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300309-JLR200

  2004cited by this paper
• Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity.

  2003cited by this paper
• Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

  2003cited by this paper
• Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

  2003cited by this paper
• Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content.

  2003cited by this paper
• Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

  2002cited by this paper
• Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

  2002cited by this paper
• Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

  2001cited by this paper
• Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.

  2001cited by this paper
• Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects

  2000cited by this paper
• Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity*

  2000cited by this paper
• Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women.

  2000cited by this paper
• Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter.

  1999cited by this paper
• Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences.

  1999cited by this paper
• Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment.

  1999cited by this paper
• The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects.

  1999cited by this paper
• Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells.

  1999cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Peroxisome proliferator activated receptor-alpha expression in human liver.

  1998cited by this paper
• A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.

  1998cited by this paper
• Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders.

  1996cited by this paper
• Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.

  1995cited by this paper
• The prevalence of side effects with regular and sustained-release nicotinic acid.

  1995cited by this paper
• Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

  1995cited by this paper
• The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression.

  1994cited by this paper
• Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.

  1990cited by this paper
• Increased β-Cell Secretory Capacity as Mechanism for Islet Adaptation to Nicotinic Acid-Induced Insulin Resistance

  1989cited by this paper
• Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance.

  1989cited by this paper
• Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.

  1986cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

  1984cited by this paper
• Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

  1984cited by this paper
• Chapter 5 Fatty acid oxidation and its regulation

  1984cited by this paper
• Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.

  1984cited by this paper
• Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man.

  1981cited by this paper
• Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia: effects of 2,2-dimethyl, 5(2, 5-xylyoxy) valeric acid therapy.

  1976cited by this paper

• The value of targeting ketone body metabolism in inflammatory and autoimmune diseases.

  2026cites this paper
• Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment

  2025cites this paper
• Mechanistic Insights into N-Oleoylethanolamide-Mediated Hepatoprotection via PPAR-α

  2025cites this paper
• Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis

  2025cites this paper
• PPARɑ variant V227A reduces plasma triglycerides through enhanced lipoprotein lipolysis

  2025cites this paper
• Nicotinic acid increases adipose tissue dietary fatty acid trapping and reduces postprandial hepatic and cardiac fatty acid uptake in prediabetes.

  2025cites this paper
• Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1.

  2025cites this paper
• Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review

  2025cites this paper
• The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα.

  2025cites this paper
• Hydroxycarboxylic Acid Receptor 2 Mediates β‐hydroxybutyrate's Antiseizure Effect in Mice

  2025cites this paper
• Calculated Excess-Triglyceride Based on the Friedewald Formula is a Possible Surrogate Marker for the Production of Large Very-Low Density Lipoprotein, A Post-Hoc Analysis of the PROUD48 Study

  2025cites this paper
• Loss of hepatic ME1 ameliorates MASLD by Suppressing peroxisomal β-Oxidation and Activating Lipophagy/Lipolysis.

  2025cites this paper
• Short-chain chlorinated paraffins at environmentally relevant doses disrupt glucose homeostasis and insulin signaling by macrophage-mediated inflammation.

  2025cites this paper
• Pparα activation stimulates autophagic flux through lipid catabolism-independent route

  2024cites this paper
• MASLD/MASH and type 2 diabetes: two sides of the same coin? From single PPAR to pan-PPAR agonists.

  2024cites this paper
• Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment

  2024cites this paper
• The effect of niacin on inflammatory markers and adipokines: a systematic review and meta-analysis of interventional studies

  2024cites this paper
• Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice.

  2024cites this paper
• Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

  2024cites this paper
• The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease

  2024cites this paper
• The Interplay between Liver and Adipose Tissue in the Onset of Liver Diseases: Exploring the Role of Vitamin Deficiency

  2024cites this paper
• Changes in glucose metabolism, C-reactive protein, and liver enzymes following intake of NAD + precursor supplementation: a systematic review and meta‐regression analysis

  2024cites this paper
• Effects of phosphorus and fenofibrate on lipid deposition, mitochondrial function and protein synthesis in obscure puffer (Takifugu obscurus)

  2024cites this paper
• Dietary Niacin Intake and Mortality Among Individuals With Nonalcoholic Fatty Liver Disease

  2024cites this paper
• Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design

  2023cites this paper
• Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease

  2023cites this paper
• Treating NASH by targeting peroxisome proliferator-activated receptors.

  2023cites this paper
• Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway.

  2023cites this paper
• The tissue‐specific metabolic effects of the PPARα agonist ciprofibrate in insulin‐resistant male individuals: a double‐blind, randomized, placebo‐controlled crossover study

  2023cites this paper
• Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials

  2023influential citation
• Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate

  2023cites this paper
• The Latest Evidence on the Association Between Vitamins and Non-alcoholic Fatty Liver Disease in Childhood

  2023cites this paper
• Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease.

  2023cites this paper
• Ficus deltoidea var. kunstleri Extract Administration in Hypercholesterolaemic, Atherosclerotic Rabbits: Effects on Organ Function, Morphology, and Atherosclerosis Development

  2023cites this paper
• Relationship between dietary intake components and hepatic fibrosis in those with obesity before and 1 year after bariatric surgery.

  2023cites this paper
• Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis

  2022cites this paper
• Impact of fenofibrate on NAFLD/NASH: a genetic perspective.

  2022cites this paper
• PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)

  2022cites this paper
• Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats

  2022cites this paper
• Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models

  2022cites this paper
• KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid

  2022cites this paper
• Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis.

  2022cites this paper
• Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

  2022cites this paper
• Is there a role of lipid-lowering therapies in the management of fatty liver disease?

  2022cites this paper
• PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

  2022cites this paper
• Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?

  2021cites this paper
• ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

  2021cites this paper
• The role of hepatic lipid composition in obesity‐related metabolic disease

  2021cites this paper
• Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome.

  2021cites this paper
• The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD

  2021cites this paper
• Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

  2021cites this paper
• The regulation of fenofibrate on lipid metabolism in obscure puffer ( Takifugu obscurus ) is dependent on dietary lipid content

  2021cites this paper
• Vitamins and non-alcoholic fatty liver disease: A molecular insight

  2021cites this paper
• Liver macrophages and inflammation in physiology and physiopathology of non‐alcoholic fatty liver disease

  2021cites this paper
• Activation of peroxisome proliferator‐activated receptor‐α stimulated lipid catabolism in liver of largemouth bass, Micropterus salmoides

  2021cites this paper
• Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?

  2021cites this paper
• Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

  2020cites this paper
• Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver

  2020cites this paper
• Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

  2020cites this paper
• Roles of peroxisome proliferator-activated receptor α in the pathogenesis of ethanol-induced liver disease.

  2020cites this paper
• Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease

  2020cites this paper
• Association between serum folate levels and fatty liver disease

  2020cites this paper
• Metabolic liver disease in diabetes – From mechanisms to clinical trials

  2020cites this paper
• Metabolic Targets in Nonalcoholic Fatty Liver Disease

  2019cites this paper
• The metabolic regulation of fenofibrate is dependent on dietary protein content in male juveniles of Nile tilapia (Oreochromis niloticus).

  2019cites this paper
• The effects of short-term low-carbohydrate and ketogenic interventions on cardiometabolic health

  2019cites this paper
• Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment

  2019cites this paper
• Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article.

  2019cites this paper
• Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention

  2019cites this paper
• Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management.

  2019cites this paper
• Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

  2019cites this paper
• Judicious Use of Lipid Lowering Agents in the Management of NAFLD

  2018cites this paper
• Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.

  2018cites this paper
• Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.

  2018cites this paper
• Hepatic fatty acid synthesis and partitioning: the effect of metabolic and nutritional state

  2018cites this paper
• Current treatment for non-alcoholic fatty liver disease

  2018cites this paper
• Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.

  2018cites this paper
• Tratamiento actual de la enfermedad por hígado graso no alcohólico

  2018cites this paper
• Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study

  2017cites this paper
• Effect of fibrates on glycemic parameters: A systematic review and meta‐analysis of randomized placebo‐controlled trials

  2017cites this paper
• Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.

  2017influential citation
• Nutritional background changes the hypolipidemic effects of fenofibrate in Nile tilapia (Oreochromis niloticus)

  2017cites this paper
• Nutrient-sensing nuclear receptors PPAR&agr; and FXR control liver energy balance

  2017cites this paper
• Nutrient-sensing nuclear receptors PPAR α and FXR control liver energy balance

  2017cites this paper
• Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments

  2017cites this paper
• Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial

  2017cites this paper
• Pharmacotherapy for Non-alcoholic Fatty Liver Disease

  2017cites this paper
• Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease

  2016cites this paper
• Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation

  2016cites this paper
• Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure

  2016cites this paper
• The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease

  2016cites this paper
• Pharmacological management of nonalcoholic fatty liver disease.

  2016cites this paper
• Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.

  2016cites this paper
• Effects of extended-release niacin on the postprandial metabolism of lipoprotein ( a ) and apolipoprotein B100-containing lipoproteins in statin-treated men with type 2 diabetes

  2016cites this paper
• A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD

  2016cites this paper
• Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

  2016cites this paper
• Non-alcoholic Fatty Liver Disease in Obesity

  2016cites this paper
• VLDL Triglyceride Kinetics in Lean, Overweight, and Obese Men and Women.

  2016cites this paper
• Effects of treatment of NAFLD on the metabolic syndrome

  2016cites this paper